PHA-739358 for the Treatment of Multiple Myeloma

• Status: Terminated
• Trial end date: 2010-09-01

Summary

The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.

• Phase: Phase 2

Details

• Lead Sponsor: Nerviano Medical Sciences